Dolutegravir plus doravirine maintains viral suppression without NRTIs
607  

Dolutegravir plus doravirine maintains viral suppression without NRTIs

A dual antiretroviral regimen containing dolutegravir (Tivicay) and boosted darunavir (Prezista) maintains viral suppression in most people who switch from a suppressive three-drug regimen, according to an observational study presented at the recent IDWeek in San Francisco. However, two drugs may not be enough for ...

November 06, 2018
News  
Studies show dolutegravir monotherapy is an unsafe switch option
628  

Studies show dolutegravir monotherapy is an unsafe switch option

Using dolutegravir alone, as maintenance treatment after achieving undetectable viral load on a three-drug regimen, results in an unacceptable rate of viral rebound and is unethical in the view of many experts, the 22nd International AIDS Conference (AIDS 2018) heard last month.

August 19, 2018
News  
Adverse Events of Raltegravir and Dolutegravir
821  

Adverse Events of Raltegravir and Dolutegravir

To compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir. Methods: All antiretroviral therapy (ART)-naïve and ART-experienced HIV-infected individuals from the Swiss HIV Cohort Study who initiated raltegravir or dolutegravir between 2006 and 2015 were investigated concerning treatment modification within the first ...

September 26, 2017
News